Health care stocks were declining premarket Friday as the Health Care Select Sector SPDR Fund (XLV) was down 0.4% and the iShares Biotechnology ETF (IBB) was 0.2% lower recently.
Novo Nordisk (NVO) shares rose past 11% after the company said its phase 1b/2a clinical trial of amycretin in people with overweight or obesity showed positive results.
Allurion Technologies (ALUR) shares surged by more than 364% after the company said it plans to initiate a clinical study to investigate the combination of the Allurion program with GLP-1 agonists to improve muscle mass and overall body composition.
Moderna (MRNA) shares were up over 1% after the company said it has been awarded a tender to supply its Covid-19 vaccine in the European Union, Norway and North Macedonia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。